Premium
Phenazone Metabolism in Patients with Liver Disease
Author(s) -
Andreasen P.B.,
Greisen G.
Publication year - 1976
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1976.tb00489.x
Subject(s) - excretion , medicine , urine , liver disease , endocrinology , renal function , metabolism , prothrombin time , liver function , liver function tests , chemistry
Phenazone metabolism was studied in 14 patients with liver disease and six normal volunteers. The plasma and renal clearance of phenazone and the 4‐hydroxyphenazone excretion in urine was significantly decreased in the patients with liver disease. The urinary excretion of 4‐hydroxyphenazone was significantly correlated to the plasma clearance of phenazone (r =+ 0.95, P < 0.001), to quantitative liver function as measured by the galactose elimination capacity (r =+ 0.95, P < 0.001), and to the prothrombin values (r =+ 0.82, P < 0.001). The determination of the 4‐hydroxyphenazone excretion in urine may be used as an easy and non‐invasive test of quantitative liver function.